Skip to content
3B BlackBio DX logo

3B BlackBio DX

3BBLACKBIO NSE
₹1,331.50 −2.10 (−0.16%)
P/E
20.58
View as Markdown
MCP
Close 4 Nov 2026 ₹1,331.50 +7.15 +0.54% 1Y
Start ₹1,324.35

Key Fundamentals

MicrocapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
25.50%
Debt to Equity
0.01
EPS (TTM)
₹64.70
Book Value
₹377.96
Market Cap
—
P/E (TTM)
20.58
P/B
3.52
ROE
19.80%
Dividend Yield
0.37%
EBITDA
₹56.78 Cr
52W High
₹1,750.00
52W Low
₹1,085.00
Day Range
₹1,311.00 – ₹1,359.30
Volume
5,670

Peer Comparison

Healthcare › Healthcare Services › Healthcare Service Provider

3B BlackBio DX peer comparison
Dr Lal Pathlabs
₹2,029.4062.75₹32,036 Cr13.580.26%22.30%28.00%₹2,891 Cr₹545 Cr
Vijaya Diagnostic Centre
₹1,424.6078.15₹14,588 Cr15.330.14%18.30%20.50%₹857 Cr₹187 Cr
Metropolis Healthcare
₹581.2559.74₹11,437 Cr8.030.88%13.60%17.80%₹1,710 Cr₹203 Cr
Thyrocare Technologies
₹495.5044.72₹7,723 Cr14.252.90%28.40%35.40%₹876 Cr₹176 Cr
Nephrocare Health Services
₹622.35148.53₹5,903 Cr5.610.00%8.83%15.30%₹1,053 Cr₹85 Cr
Suraksha Diagnostic
₹333.0548.41₹1,717 Cr7.080.15%14.20%17.30%₹325 Cr₹35 Cr
Krsnaa Diagnostics
₹483.0515.84₹1,571 Cr1.510.41%10.90%12.70%₹726 Cr₹98 Cr
3B BlackBio DX (this company)
₹1,331.5020.58₹1,147 Cr3.520.37%19.80%25.50%₹153 Cr₹56 Cr
Median 8 companies₹601.8054.08₹6,813 Cr7.560.32%16.25%19.15%₹867 Cr₹137 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

69 Strong

Data confidence 100/100

Category scores

Quality
76
Strong
Returns, margins, earnings quality 22% weight
Valuation
71
Strong
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
91
Strong
Solvency, leverage, coverage 9% weight
Momentum
36
Poor
Trend strength, vol-adjusted 12% weight
Ownership
55
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company's median sales growth is 21.9% of last 10 years

Weaknesses

1
  • Earnings include an other income of Rs.27.4 Cr.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1162
OscillatorsBearish261
Moving AveragesStrong Bearish901

Key readings

RSI (14)
42.38
Neutral
MACD (12,26,9)
−38.35
Bearish
SMA (50)
1,435.20
Bearish
SMA (200)
1,343.94
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+23.65%
5Y−8.96%
3Y+31.82%
1Y+47.92%
TTM+54.30%

Net profit

Net profit growth by window
10YZero base
5Y−12.05%
3Y+32.15%
1Y+25.00%
TTM+14.72%

Operating cash flow

Operating cash flow growth by window
10Y+48.46%
5Y−11.90%
3Y+37.51%
1Y+20.93%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+28.38 pp
5Y−25.94 pp
3Y−6.63 pp
1Y−11.94 pp
TTM−16.46 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹16.00 Cr
Mar 2018₹23.00 Cr
Mar 2019₹23.00 Cr
Mar 2020₹29.00 Cr
Mar 2021₹227 Cr
Mar 2022₹81.00 Cr
Mar 2023₹62.00 Cr
Mar 2024₹74.00 Cr
Mar 2025₹96.00 Cr
Mar 2026₹142 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹1.00 Cr
Mar 2018₹3.00 Cr
Mar 2019₹5.00 Cr
Mar 2020₹8.00 Cr
Mar 2021₹114 Cr
Mar 2022₹32.00 Cr
Mar 2023₹26.00 Cr
Mar 2024₹32.00 Cr
Mar 2025₹48.00 Cr
Mar 2026₹60.00 Cr

Quarterly Results

₹ Cr
532067 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
14.28
19.18
17.67
23
19.43
29.15
25.39
22.5
22.23
33.9
50.35
35.43
33.49
Expenses
7.84
11.39
8.8
13.12
8.48
12.98
10.32
14.58
10.4
19.17
28.63
26.94
24.97
Operating Profit
6.44
7.79
8.87
9.88
10.95
16.17
15.07
7.92
11.83
14.73
21.72
8.49
8.52
OPM %
45.1%
40.62%
50.2%
42.96%
56.36%
55.47%
59.35%
35.2%
53.22%
43.45%
43.14%
23.96%
25.44%
Other Income
2.96
2.75
2.63
4.19
3.69
3.44
3.01
4.94
4.32
5.51
5.59
10.15
6.14
Interest
0.02
0.04
0.03
0.04
0.01
0.03
0.02
0.04
0.01
0.04
0.09
0.1
0.1
Depreciation
0.19
0.24
0.32
0.3
0.27
0.27
0.27
0.28
0.28
0.58
0.38
3.89
1.34
PBT
9.19
10.26
11.15
13.73
14.36
19.31
17.79
12.54
15.86
19.62
26.84
14.65
13.22
Tax %
21.55%
26.02%
23.68%
35.98%
21.31%
22.99%
24.17%
35.89%
20.3%
23.34%
16.39%
33.11%
32.07%
Net Profit
7.21
7.58
8.51
8.79
11.3
14.87
13.49
8.04
12.65
15.04
22.44
9.81
8.98
EPS (₹)
9.71
10.46
10.16
10.33
12.97
17.07
15.61
9.79
14.67
17.14
25.32
11.14
11.1

Profit & Loss

₹ Cr
532067 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
19
17
16
23
23
29
227
81
62
74
96
142
153
Expenses
18
16
14
18
16
20
77
44
33
41
46
85
100
Operating Profit
1
2
3
5
7
9
150
37
29
33
50
57
53
OPM %
7%
9%
16%
23%
31%
32%
66%
46%
47%
44%
52%
40%
35%
Other Income
0
0
0
0
1
2
3
7
7
13
15
26
27
Interest
1
1
1
1
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
1
1
1
1
1
1
1
5
6
PBT
0
0
1
5
7
10
152
43
35
44
64
77
74
Tax %
23%
23%
19%
24%
25%
23%
25%
26%
27%
28%
25%
22%
—
Net Profit
0
0
1
3
5
8
114
32
26
32
48
60
56
EPS (₹)
0.36
0.51
1.76
5.35
8.18
10.24
152
42.89
34.55
37.4
55.57
68.27
64.7
Div. Payout %
0%
0%
17%
9%
6%
7%
6%
24%
8%
8%
7%
7%
—

Balance Sheet

₹ Cr
532067 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6
6
6
6
6
7
7
7
9
9
9
9
Reserves
4
4
5
12
16
25
125
146
185
214
260
316
Borrowings
8
8
9
6
6
4
2
3
2
1
0
3
Other Liabilities
7
6
6
6
8
9
59
37
19
24
27
51
Total Liabilities
25
24
26
30
36
45
194
192
214
248
296
378
Fixed Assets
4
3
3
4
4
4
5
7
8
7
7
28
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
1
59
93
92
117
156
158
Other Assets
21
21
22
26
32
40
130
93
114
123
132
193
Total Assets
25
24
26
30
36
45
194
192
214
248
296
378

Cash Flow

₹ Cr
532067 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
1
1
2
4
7
98
37
20
27
43
52
Investing
0
0
0
−1
−1
−1
−70
−28
15
−20
−33
−24
Financing
0
−1
0
0
−1
1
−2
−15
−5
−4
−3
−1
Net Cash Flow
0
0
0
1
2
7
26
−6
30
3
7
28
Free Cash Flow
0
1
0
1
3
6
96
35
18
26
42
27
CFO/EBITDA
23
69
36
52
71
101
90
129
100
115
116
121

Ratios

532067 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
262
283
321
259
290
252
56
136
200
179
138
129
Inventory Days
145
143
175
—
—
—
—
—
164
141
124
187
Days Payable
218
203
186
—
—
—
—
—
69
66
28
70
Cash Conversion Cycle
188
223
310
259
290
252
56
136
296
253
235
245
Working Capital Days
175
205
247
253
287
275
65
162
241
215
169
143
ROCE %
7%
7%
13%
24%
28%
31%
162%
27%
19%
21%
26%
25%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view 3B BlackBio DX insights

42 extracted metrics across FY13–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 40.95%
  • Public 37.06%
  • Others 17.21%
  • FIIs 2.46%
  • DIIs 2.33%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about 3B BlackBio DX

What does 3B Blackbio DX Ltd do?
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products
Where is 3B Blackbio DX Ltd (3BBLACKBIO) listed?
3B Blackbio DX Ltd trades as 3BBLACKBIO on the NSE and under code 532067 on the BSE.
Which sector does 3B Blackbio DX Ltd belong to?
3B Blackbio DX Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the PE ratio of 3B Blackbio DX Ltd?
3B Blackbio DX Ltd trades at a PE ratio of 20.58 as of 4 Nov 2026, on earnings per share of ₹64.7, against a book value of ₹377.96 per share.
What is the 52-week high and low of 3B Blackbio DX Ltd?
Over the last 52 weeks 3B Blackbio DX Ltd has traded between ₹1,085 and ₹1,750 as of 4 Nov 2026.
Does 3B Blackbio DX Ltd pay dividends?
3B Blackbio DX Ltd has a dividend yield of 0.37%.
What is the Return on Equity (ROE) of 3B Blackbio DX Ltd?
3B Blackbio DX Ltd reported a return on equity of 19.80%. Its debt-to-equity ratio is 0.01.

Company Information

Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products

Website kilpest.com
Listed 20 Apr 2026
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/532067.md for 3B Blackbio DX Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month